Greenpro Capital Corp.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
GRNQ$7.10+1.4%Stored close · as of Nov 6, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2026-03-31; filed 2026-05-08.
0001493152-26-021825
Item 1A. Risk FactorsUNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDSDEFAULTS UPON SENIOR SECURITIESMINE SAFETY DISCLOSURESOTHER INFORMATIONCurrent report: 10-Q
Period ended 2026-06-30; filed 2026-08-05.
0001493152-26-036089
Item 1A. RISK FACTORSUNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDSDEFAULTS UPON SENIOR SECURITIESMINE SAFETY DISCLOSURESOTHER INFORMATIONThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 28 previous paragraphs and 30 current paragraphs.
18 unchanged; 2 reworded; 10 added; 8 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 4 previous and 4 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
The current filing states there were no material changes to risk factors.
This is the filer’s own statement, not a conclusion from the comparison. Read its qualifications and the report it references.
Current filing’s statement
There have been no material changes to the risk factors disclosed in Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. For convenience, those risk factors are reproduced below in their entirety.
Added paragraphs (10)
Current report
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Current report
The issuances described below were made in transactions not involving a public offering. In connection with the issuances, the Company relied upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D and/or Regulation S promulgated thereunder, as applicable to each issuance. The securities were issued as restricted securities and are subject to applicable limitations on transfer.
Current report
On April 16, 2026, the Company acquired 0.99% shareholdings of Greenophene Technologies Limited, a company incorporated in the British Virgin Islands (“Greenophene”) from Lim Chee Yin, a shareholder of Greenophene (the “Seller”) in exchange by issuance of 800,000 shares of the Company’s Common Stock to the Seller, valued at $1.50 per share or an aggregate value of $1,200,000.
Current report
Issuance of 201,850 shares from April 28 to June 30, 2026
Current report
From April 28 to June 30, 2026, the Company sold and issued in aggregate 201,850 shares of its Common Stock to its Chief Executive Officer, President and Director, Mr. Lee, Chong Kuang (“Mr. Lee”) in private placements at total cash proceeds of $400,000. The Company plans to use the proceeds for operating capital.
Current report
A list of the issuance of the Company’s Common Stock during the six months ended June 30, 2026, is set forth below:
Current report
Item 3. Defaults upon Senior Securities.
Removed paragraphs (8)
Previous report
On March 31, 2026 (the “Closing Date”), all conditions for closing were satisfied, and the Company consummated the transactions contemplated by the Share Exchange Agreement. At closing, the Company acquired 1,360 ordinary shares of Forekast from the Forekast Shareholders, representing 13.6% of Forekast’s outstanding equity interests on a fully diluted basis as of the Closing Date. In consideration therefor, the Company issued to the Forekast Shareholders an aggregate of 8,500,000 shares of its common stock, par value $0.0001 (the “Common Stock”), valued at $17,000,000 to the Forekast Shareholders, such shares constituting the “Exchange Shares”. The transaction constituted a minority investment in Forekast and did not result in the Company obtaining control of Forekast.
Previous report
Set forth below are the details of the Company’s issuance of Common Stock in connection with the minority investment in Forekast described above, as extracted from Annex A to the Share Exchange Agreement during the three months ended March 31, 2026:
Previous report
As of the date of this report, the Company has total 18,033,123 shares of Common Stock issued and outstanding and the Forekast Shareholders collectively hold approximately 47% of the Company’s Common Stock upon the receipt of 8,500,000 shares of Common Stock from the Company.
Previous report
On November 18, 2025, the Company entered into an acquisition agreement (the “Acquisition Agreement”) with Lim Chee Yin, an individual (the “Seller”). Pursuant to the Acquisition Agreement, subject to the satisfaction or waiver of the conditions set forth therein, upon consummation of the transaction contemplated in the Acquisition Agreement (the “Closing”), the Company acquired 0.99% of Seller’s shareholdings in Greenophene Technologies Limited, a company incorporated in the British Virgin Islands (“Greenophene”), equivalent to 10 shares of Greenophene (the “Acquisition”).
Previous report
On April 16, 2026 (the “Closing Date”), all conditions to closing were satisfied, and the Company consummated the transactions contemplated by the Acquisition Agreement. At the Closing, the Company acquired 10 ordinary shares of Greenophene from the Seller, representing a minority interest of 0.99% of Greenophene’s outstanding equity interests as of the Closing Date. In consideration therefor, the Company issued to the Seller 800,000 restricted shares of the Company’s common stock, par value $0.0001 (the “Common Stock”), valued at $1.50 per share, for an aggregate value of $1,200,000 (the “Consideration”).
Previous report
As of the date of this report, the Company has total 18,033,123 shares of Common Stock issued and outstanding and the Seller holds approximately 4.4% of the Company’s Common Stock upon the receipt of 800,000 shares of Common Stock from the Company.
Previous report
Issuance of 107,310 shares on April 28, 2026
Previous report
On April 28, 2026, we entered into a subscription agreement (the “Subscription Agreement”) with our Chief Executive Officer, President and Director, Mr. Lee Chong Kuang, (the “Purchaser”) providing for the private placement of 107,310 shares of Common Stock at a per share purchase price of $2.3297 (the “Offering”) for aggregate gross proceeds of $250,000. The Offering closed on April 28, 2026.
Reworded paragraphs (2)
Previous wording
Except as set forth below, there have been no material changes to the risk factors disclosed in our Quarterly Report on Form 10-Q for the three months ended March 31, 2026. The following additional risk factors relate primarily to our subsidiary, Green-X Corp. (“Green-X”), and its digital-asset exchange operations and reflect material developments in the blockchain and digital-asset industry since that filing.
Current wording
There have been no material changes to the risk factors disclosed in Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. For convenience, those risk factors are reproduced below in their entirety.
Previous wording
On February 13, 2026, the Company entered into a share exchange agreement (the “Share Exchange Agreement”) with Forekast Limited, a company formed under the laws of the British Virgin Islands (“Forekast”) and the shareholders of Forekast listed on Annex A thereto (the “Forekast Shareholders”).
Current wording
On March 31, 2026, the Company acquired a 13.6% equity interest of Forekast Limited, a company formed under the laws of the British Virgin Islands (“Forekast”) in exchange by issuance of 8,500,000 shares of its Common Stock to the shareholders of Forekast Limited (the “Forekast Shareholders”), valued at $17,000,000 to the Forekast Shareholders.